Online inquiry

IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5907MR)

This product GTTS-WQ5907MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL31RA gene. The antibody can be applied in Atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001242636.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 133396
UniProt ID Q8NI17
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ5907MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4369MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ3206MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ11839MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-4280
GTTS-WQ434MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 3C23K
GTTS-WQ799MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ12978MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ5313MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ5038MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW